Technical Analysis for MVRBF - Medivir Ser B Sek5

Grade Last Price % Change Price Change
grade D 2.0 17.65% 0.3000
MVRBF closed up 17.65 percent on Monday, June 17, 2019, on 50 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical MVRBF trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Up Strength 0.00%
New 52 Week Closing Low Bearish 17.65%
Stochastic Buy Signal Bullish 17.65%
Hot IPO Pullback Bullish Swing Setup 17.65%
Narrow Range Bar Range Contraction 17.65%
New 52 Week Low Weakness 17.65%
Down 3 Days in a Row Weakness 17.65%
Down 4 Days in a Row Weakness 17.65%

Older signals for MVRBF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Europe, the Nordic region, the United States, and the rest of the world. The company's products portfolio includes Remetinostat, which has completed Phase II clinical study for use in the treatment of cutaneous T-cell lymphoma; Birinapant in combination with Keytruda that is in phase I/II study for treating solid tumors; and MIV-711, which is in Phase IIa study that is used for the treatment of osteoarthritis, as well as MIV-818, a preclinical stage nucleoside pro-drug for treating patients with advanced liver cancers. Its products also include Xerclear for use in the treatment of labial herpes in Europe and the rest of the world; MIV-802, a pan-genotypic nucleotide-based inhibitor of the hepatitis C virus NS5B polymerase, which is in preclinical development in Greater China; and Simeprevir/OLYSIO, an antiviral combination treatment regimen for chronic genotype 1 and 4 hepatitis C infection in adult patients with liver disease, including cirrhosis. Medivir AB (publ) was founded in 1988 and is headquartered in Huddinge, Sweden.
Chemistry Medicine RTT Pharmaceuticals Solid Tumors Osteoarthritis Organic Chemistry Hepatocellular Carcinoma Infectious Causes Of Cancer Healthcare Associated Infections Hepatitis C Cirrhosis Cyclopropanes Liver Disease Treatment Of Osteoarthritis Cutaneous T Cell Lymphoma Sulfonamides
Is MVRBF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 8.5
52 Week Low 1.7
Average Volume 1,794
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 4.1286
10-Day Moving Average 2.4522
Average True Range 0.4987
ADX 0.0
+DI 19.4438
-DI 80.5562
Chandelier Exit (Long, 3 ATRs ) 7.0039
Chandelier Exit (Short, 3 ATRs ) 3.1961
Upper Bollinger Band 8.2008
Lower Bollinger Band 0.0564
Percent B (%b) 0.24
BandWidth 197.267839
MACD Line -1.1551
MACD Signal Line -0.7613
MACD Histogram -0.3938
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.0000
Resistance 3 (R3) 2.0000 2.0000 2.0000
Resistance 2 (R2) 2.0000 2.0000 2.0000 2.0000
Resistance 1 (R1) 2.0000 2.0000 2.0000 2.0000 2.0000
Pivot Point 2.0000 2.0000 2.0000 2.0000 2.0000
Support 1 (S1) 2.0000 2.0000 2.0000 2.0000 2.0000
Support 2 (S2) 2.0000 2.0000 2.0000 2.0000
Support 3 (S3) 2.0000 2.0000 2.0000
Support 4 (S4) 2.0000